Press Releases
Immunomic Therapeutics to Present at the First International Symposium on Merkel Cell Carcinoma 2019
Press Press ReleasesData demonstrates that UNITE, as a nucleic acid platform, elicits potent immune responses ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. will present data on its investigational nucleic acid platform, UNITE (UNiversalRead moreImmunomic Therapeutics to Present at Precision Lung Cancer World R&D Summit
Press Press ReleasesDiscussion of UNITE platform as applied in cancer immunotherapy BOSTON--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. announced today a presentation at the Precision Lung Cancer World R&D Summit in Boston. On Tuesday,Read more- Featured Highlights Press Press Releases- ITI-1000 targets CMV with Immunomic Therapeutics’ immunotherapy UNITE™ platform - ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. announced today that it has assumed sponsorship of the Investigational New Drug (IND)Read more
- Featured Press Press ReleasesROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that it has appointed brain tumor expert E. Antonio ‘Nino’ Chiocca, M.D., Ph.D., Harvey W.Read more
Immunomic Therapeutics Appoints Andrew Eisen, M.D., Ph.D. as VP, Clinical Development
Featured Press Press ReleasesJuly 12, 2019 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the appointment of Andrew Eisen, M.D., Ph.D. asRead moreImmunomic Therapeutics Announces Promotion of Teri Heiland, Ph.D. to Chief Scientific Officer
Featured Press Press ReleasesJune 20, 2019 20:05 UTC ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the promotion of Teri Heiland, Ph.D. to Chief Scientific Officer.Read moreImmunomic Therapeutics to Present at China Focus @BIO Philadelphia
Press ReleasesMay 30, 2019 04:05 PM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company will present at the ChinaRead moreImmunomic Therapeutics to Participate at Sachs’ 5th Annual Immuno-Oncology BD&L and Investment Forum
Press ReleasesMay 24, 2019 20:05 UTC ROCKVILLE, Md.--(BUSINESS WIRE)-- Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company will present at the 5th Annual Immuno-oncologyRead moreImmunomic Therapeutics to Participate at World Vaccine Congress Washington 2019
Press Press ReleasesApril 04, 2019 04:05 PM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that it will participate at the World Vaccine Congress Washington being held in Washington, D.C.Read more- Featured Press Press ReleasesFebruary 28, 2019 04:05 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that a poster will be presented by Immunomic scientists at the American Association for CancerRead more
Immunomic Therapeutics to Sponsor and Present at CHCI Health Summit
Press Press ReleasesImmunomic Therapeutics to Sponsor and Present at CHCI Health Summit February 26, 2019 04:05 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that its’ Senior ViceRead moreImmunomic Therapeutics Licenses Investigational Canine Dermatitis Therapy to ZENOAQ
Featured Press Press ReleasesFebruary 06, 2019 05:00 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company has granted Japanese animalRead more